相似文献
1
Treatment of HCV in persons who inject drugs: Treatment as prevention.对注射毒品者的丙型肝炎治疗：治疗即预防。
Clin Liver Dis (Hoboken). 2017 Apr 20;9(4):77-80. doi: 10.1002/cld.626. eCollection 2017 Apr.
2
Hepatitis C virus treatment as prevention in an extended network of people who inject drugs in the USA: a modelling study.美国扩大的注射吸毒者网络中丙型肝炎病毒治疗作为预防措施：一项建模研究。
Lancet Infect Dis. 2018 Feb;18(2):215-224. doi: 10.1016/S1473-3099(17)30676-X. Epub 2017 Nov 15.
3
Modeling the Impacts of Prevention and Treatment Interventions on Hepatitis C Among People Who Inject Drugs in China.模拟预防和治疗干预措施对中国注射吸毒人群丙型肝炎的影响。
Infect Dis Ther. 2023 Apr;12(4):1043-1055. doi: 10.1007/s40121-023-00779-0. Epub 2023 Mar 9.
4
Ten priorities for expanding access to HCV treatment for people who inject drugs in low- and middle-income countries.扩大低收入和中等收入国家注射吸毒者获得丙型肝炎病毒治疗机会的十项优先事项。
Int J Drug Policy. 2015 Nov;26(11):1088-93. doi: 10.1016/j.drugpo.2015.05.004. Epub 2015 May 18.
5
State HCV Incidence and Policies Related to HCV Preventive and Treatment Services for Persons Who Inject Drugs - United States, 2015-2016.2015 - 2016年美国注射吸毒者的丙型肝炎病毒（HCV）发病率及与HCV预防和治疗服务相关的政策
MMWR Morb Mortal Wkly Rep. 2017 May 12;66(18):465-469. doi: 10.15585/mmwr.mm6618a2.
6
Review article: treatment as prevention - targeting people who inject drugs as a pathway towards hepatitis C eradication.综述文章：治疗即预防 - 将注射毒品者作为消除丙型肝炎的途径。
Aliment Pharmacol Ther. 2016 Jul;44(2):145-56. doi: 10.1111/apt.13673. Epub 2016 May 20.
7
Age and gender-specific hepatitis C continuum of care and predictors of direct acting antiviral treatment among persons who inject drugs in Seattle, Washington.年龄和性别特异性丙型肝炎连续护理以及华盛顿州西雅图注射吸毒者直接作用抗病毒治疗的预测因素。
Drug Alcohol Depend. 2021 Mar 1;220:108525. doi: 10.1016/j.drugalcdep.2021.108525. Epub 2021 Jan 11.
8
Prevalence of and risk factors for hepatitis C virus antibody among people who inject drugs in Cambodia: a national biological and behavioral survey.柬埔寨注射吸毒人群中丙型肝炎病毒抗体的流行情况及危险因素：一项全国性的生物与行为调查。
Harm Reduct J. 2019 Apr 29;16(1):29. doi: 10.1186/s12954-019-0299-1.
9
Interventions to enhance testing and linkage to treatment for hepatitis C infection for people who inject drugs: A systematic review and meta-analysis.干预措施以提高注射毒品者丙型肝炎感染的检测和治疗关联：系统评价和荟萃分析。
Int J Drug Policy. 2023 Jan;111:103917. doi: 10.1016/j.drugpo.2022.103917. Epub 2022 Dec 19.
10
HCV/HIV coinfection among people who inject drugs and enter opioid substitution treatment in Greece: prevalence and correlates.希腊接受阿片类药物替代治疗的注射吸毒者中的丙型肝炎病毒/艾滋病病毒合并感染：患病率及其相关因素
Hepatol Med Policy. 2016 Aug 25;1:9. doi: 10.1186/s41124-016-0017-5. eCollection 2016.
引用本文的文献
1
Combining treatment for chronic hepatitis C with opioid agonist therapy is an effective microelimination strategy for people who inject drugs with high risk of non-adherence to direct-acting antiviral therapy.将慢性丙型肝炎治疗与阿片类激动剂疗法相结合，对于有不坚持直接抗病毒治疗高风险的注射吸毒者而言，是一种有效的微观消除策略。
J Virus Erad. 2023 Mar 2;9(1):100319. doi: 10.1016/j.jve.2023.100319. eCollection 2023 Mar.
2
Telemedicine successfully engages marginalized rural hepatitis C patients in curative care.远程医疗成功地让边缘化的农村丙肝患者参与到治愈性治疗中。
J Assoc Med Microbiol Infect Dis Can. 2020 Jun 23;5(2):87-97. doi: 10.3138/jammi-2019-0025. eCollection 2020 Jun.
3
The role of prevention strategies in achieving HCV elimination in Canada: what are the remaining challenges?预防策略在加拿大实现丙型肝炎病毒消除中的作用：尚存哪些挑战？
Can Liver J. 2018 Jul 17;1(2):4-13. doi: 10.3138/canlivj.1.2.003. eCollection 2018 Spring.
4
Real-world outcomes of rapid regional hepatitis C virus treatment scale-up among people who inject drugs in Tayside, Scotland.苏格兰泰赛德地区注射吸毒人群中丙型肝炎病毒快速区域治疗扩大化的真实世界结局。
Aliment Pharmacol Ther. 2022 Mar;55(5):568-579. doi: 10.1111/apt.16728. Epub 2021 Dec 8.
5
HCV communication within ego-centric networks of men and women who inject drugs.HCV 在注射吸毒的男性和女性以自我为中心的网络内的传播。
Drug Alcohol Depend. 2021 Dec 1;229(Pt B):109157. doi: 10.1016/j.drugalcdep.2021.109157. Epub 2021 Oct 29.
6
Beyond clinical outcomes: the social and healthcare system implications of hepatitis C treatment.超越临床结果：丙型肝炎治疗的社会和医疗体系影响。
BMC Infect Dis. 2020 Sep 24;20(1):702. doi: 10.1186/s12879-020-05426-4.
7
Competing priorities and second chances - A qualitative exploration of prisoners' journeys through the Hepatitis C continuum of care.竞争的优先级和第二次机会——对囚犯通过丙型肝炎连续护理过程的定性探索。
PLoS One. 2019 Sep 11;14(9):e0222186. doi: 10.1371/journal.pone.0222186. eCollection 2019.
8
Hepatitis C virus screening and treatment in Irish prisons from nurse managers' perspectives - a qualitative exploration.从护士管理者视角看爱尔兰监狱中的丙型肝炎病毒筛查与治疗——一项质性探索
BMC Nurs. 2019 Jun 13;18:23. doi: 10.1186/s12912-019-0347-x. eCollection 2019.
本文引用的文献
1
Corrigendum to 'EASL recommendations on treatment of hepatitis C: Final update of the series [J Hepatol 73 (2020) 1170-1218].《欧洲肝脏研究学会丙型肝炎治疗推荐：系列最终更新版》勘误 [《肝脏病学杂志》73卷（2020年）1170 - 1218页]
J Hepatol. 2023 Feb;78(2):452. doi: 10.1016/j.jhep.2022.10.006. Epub 2022 Dec 1.
2
Hepatitis C Guidance 2019 Update: American Association for the Study of Liver Diseases-Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection.《2019年丙型肝炎指南更新：美国肝病研究协会-美国传染病学会关于丙型肝炎病毒感染检测、管理及治疗的建议》
Hepatology. 2020 Feb;71(2):686-721. doi: 10.1002/hep.31060.
3
Direct-acting antiviral agents for HCV infection affecting people who inject drugs.直接作用抗病毒药物治疗影响注射吸毒人群的 HCV 感染。
Nat Rev Gastroenterol Hepatol. 2017 Nov;14(11):641-651. doi: 10.1038/nrgastro.2017.106. Epub 2017 Aug 23.
4
Efficacy and Safety of Sofosbuvir/Velpatasvir in Patients With Chronic Hepatitis C Virus Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ASTRAL Trials.索磷布韦/维帕他韦在接受阿片类药物替代疗法的慢性丙型肝炎病毒感染患者中的疗效和安全性：3期ASTRAL试验分析
Clin Infect Dis. 2016 Dec 1;63(11):1479-1481. doi: 10.1093/cid/ciw579. Epub 2016 Aug 23.
5
Efficacy and Safety of Ledipasvir/Sofosbuvir With and Without Ribavirin in Patients With Chronic HCV Genotype 1 Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ION Trials.在接受阿片类药物替代治疗的慢性 HCV 基因 1 型感染患者中，使用 Ledipasvir/Sofosbuvir 联合或不联合利巴韦林的疗效和安全性：ION 三期试验分析。
Clin Infect Dis. 2016 Dec 1;63(11):1405-1411. doi: 10.1093/cid/ciw580. Epub 2016 Aug 23.
6
Elbasvir-Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy: A Randomized Trial.依巴司韦/格拉瑞韦治疗接受阿片类激动剂治疗的丙型肝炎病毒感染者：一项随机试验。
Ann Intern Med. 2016 Nov 1;165(9):625-634. doi: 10.7326/M16-0816. Epub 2016 Aug 9.
7
Recommendations for the management of hepatitis C virus infection among people who inject drugs.注射吸毒者丙型肝炎病毒感染管理建议
Int J Drug Policy. 2015 Oct;26(10):1028-38. doi: 10.1016/j.drugpo.2015.07.005. Epub 2015 Jul 17.
8
Grazoprevir-Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection: A Randomized Trial.格卡瑞韦哌仑他韦联合治疗方案治疗初治的慢性丙型肝炎病毒基因 1、4 或 6 型感染的肝硬化和非肝硬化患者：一项随机试验。
Ann Intern Med. 2015 Jul 7;163(1):1-13. doi: 10.7326/M15-0785.
9
Ombitasvir/paritaprevir/r and dasabuvir plus ribavirin in HCV genotype 1-infected patients on methadone or buprenorphine.奥贝他韦/帕利瑞韦/达塞布韦联合利巴韦林治疗接受美沙酮或丁丙诺啡维持治疗的 HCV 基因 1 型感染患者。
J Hepatol. 2015 Aug;63(2):364-9. doi: 10.1016/j.jhep.2015.03.029. Epub 2015 Apr 1.
10
Mixed HCV infection and reinfection in people who inject drugs--impact on therapy.混合 HCV 感染和再感染在注射毒品者中的情况 - 对治疗的影响。
Nat Rev Gastroenterol Hepatol. 2015 Apr;12(4):218-30. doi: 10.1038/nrgastro.2015.36. Epub 2015 Mar 17.
Zotero 插件